Mumbai, June 21, 2017: Pharma Major,Cadila Healthcare Ltd (Zydus Cadila) today said it has received final approval from the USFDA to market Diflunisal tablets in the strength of 500 mg.
It is a non-steroidal anti-inflammatory drug (NSAID) and will be produced at the group’s formulations manufacturing facility at Baddi, Himachal Pradesh, company said in a filing with BSE.
United News of India
By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…
Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…
New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…
National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…
Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…
New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…